Enhancing innate immunity against virus in times of COVID-19: trying to untangle facts from fictions

Autor: Alan Estrada-Cardona, María Isabel Rojo-Gutiérrez, Désirée Larenas-Linnemann, César Fireth Pozo-Beltrán, Ernesto Onuma-Takane, Blanca Estela Del Río-Navarro, María Virginia Blandón-Vijil, Jorge A. Luna-Pech, J. E. Gereda, Noel Rodríguez-Pérez, Alfredo Arias-Cruz, Elsy Maureen Navarrete-Rodríguez
Jazyk: angličtina
Rok vydání: 2020
Předmět:
BV
Bacterial vaccine

mindfulness
ACE2
Angiotensin converting enzime-2

Systemic inflammatory response syndrome
TCR :T-cell receptor

APC
Antigen-presenting cell

Heat shock proteins
HLA-DR

bacterial vaccine
Immunoglobulin
IGFBP6

immune response
DLE
Dialyzable leukocyte extract

PPD
Purified protein derivative (tuberculin)

trained immunity
MCP-1
Monocyte chemoattractant protein-1

NK
Natural killer

Gαs: G protein coupled receptor alfa-subunits
HSP

Rapid eye movement
RIPK2

Pandemic
Immunology and Allergy
TNF-α
Tumor necrosis factor alpha

R0 : Basic reproduction number
REM

PUFA
Polyunsaturated fatty acid

NOD2
Nucleotide-binding oligomerization domain-containing protein 2

Toll-like receptor
Reactive oxygen species
SARS-CoV-2

Respiratory tract infections
exercise
CNS
Central nervous system

Interferon
IG

MMR
DC
Dendritic cell

Bacterial vaccine
Reactive nitrogen species
ROS

PKC
Protein kinase C

BCG
Bacillus Calmette-Guérin

DAMPs
Damage-associated molecular patterns

TLR
Toll-like receptor

Pulmonary and Respiratory Medicine
lcsh:Immunologic diseases. Allergy
medicine.medical_specialty
Interleukin
MBSR

CCL-5
Chemokine (C-C motif) ligand 5

Immunology
Insulin-like growth-factor-binding-protein 6
IL

Major histocompatibility complex class II cell surface receptor
ICAM-1

COVID-19
Coronavirus disease-2019

Article
OxPhos: Oxidative phosphorylation
PAMPs

Immune system
Immunity
NK-cell
URTI
Upper-respiratory tract infection

Bacillus Calmette-Guérin
medicine
innate
Intercellular adhesion molecule type 1
IFN

MODS
Multi-organ dysfunction syndrome

NF-κB
Nuclear factor kappaB

sleep
Intensive care medicine
Innate immune system
Severe acute respiratory syndrome coronavirus 2
SIRS

business.industry
CI
Confidence interval

Pathogen-associated molecular patterns
PBMC

COVID-19
Mindfulness-based stress reduction
mCa++: Intramitochondrial calcium

Review article
MyD88
Myeloid differentiation primary response 88

TRPV
Thermolabile calcium channels

CXCR3A
CXC chemokine receptor 3A

Receptor iteracting serine/threonine kinase 2
RNA

Ribonucleic acid
RNS

business
lcsh:RC581-607
Peripheral blood mononuclear cell
PI3K/Akt: Phosphatidylinositol 3-kinase pathway

OR
Odds ratio

Th
T helper-cell
Zdroj: The World Allergy Organization Journal
World Allergy Organization Journal, Vol 13, Iss 11, Pp 100476-(2020)
World Allergy Organization Journal
ISSN: 1939-4551
Popis: Introduction In light of the current COVID-19 pandemic, during which the world is confronted with a new, highly contagious virus that suppresses innate immunity as one of its initial virulence mechanisms, thus escaping from first-line human defense mechanisms, enhancing innate immunity seems a good preventive strategy. Methods Without the intention to write an official systematic review, but more to give an overview of possible strategies, in this review article we discuss several interventions that might stimulate innate immunity and thus our defense against (viral) respiratory tract infections. Some of these interventions can also stimulate the adaptive T- and B-cell responses, but our main focus is on the innate part of immunity. We divide the reviewed interventions into: 1) lifestyle related (exercise, >7 h sleep, forest walking, meditation/mindfulness, vitamin supplementation); 2) Non-specific immune stimulants (letting fever advance, bacterial vaccines, probiotics, dialyzable leukocyte extract, pidotimod), and 3) specific vaccines with heterologous effect (BCG vaccine, mumps-measles-rubeola vaccine, etc). Results For each of these interventions we briefly comment on their definition, possible mechanisms and evidence of clinical efficacy or lack of it, especially focusing on respiratory tract infections, viral infections, and eventually a reduced mortality in severe respiratory infections in the intensive care unit. At the end, a summary table demonstrates the best trials supporting (or not) clinical evidence. Conclusion Several interventions have some degree of evidence for enhancing the innate immune response and thus conveying possible benefit, but specific trials in COVID-19 should be conducted to support solid recommendations.
Databáze: OpenAIRE